# EDGAR Filing Document

**Accession Number:** 0001533743
**File Stem:** 0000000000-25-008277
**Filing Date:** 2025-8
**Character Count:** 2767
**Document Hash:** 7a9f174394cbe9ee8f8d6d2804be212d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008277.hdr.sgml**: 20260115

**ACCESSION NUMBER**: 0000000000-25-008277

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250806

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Processa Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001533743
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 451539785
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-39531

**BUSINESS ADDRESS:**
- **STREET 1:** 601 21ST STREET, SUITE 300
- **CITY:** VERO BEACH
- **STATE:** FL
- **ZIP:** 32960
- **BUSINESS PHONE:** 443-776-3133

**MAIL ADDRESS:**
- **STREET 1:** 601 21ST STREET, SUITE 300
- **CITY:** VERO BEACH
- **STATE:** FL
- **ZIP:** 32960

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Heatwurx, Inc.
- **DATE OF NAME CHANGE:** 20111028
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-25-011519

## Text-Extract

```

                                                           August 6, 2025

Russell Skibsted
Chief Financial Officer
Processa Pharmaceuticals, Inc.
601 21st Street, Suite 300
Vero Beach, FL, 32960

       Re: Processa Pharmaceuticals, Inc.
           Preliminary Proxy Statement on Schedule 14A
           Filed July 31, 2025
           File No. 001-39531
Dear Russell Skibsted:

       We have reviewed your filing and have the following comment.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response. After
reviewing your response to this letter, we may have additional comments.

Preliminary Proxy Statement on Schedule 14A
General

1.     Please revise the preliminary proxy statement to fill in the number of
authorized
       shares in proposal number 1 and the reverse stock split ratios in
proposal number 2.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Please contact Chris Edwards at 202-551-6761 or Joe McCann at
202-551-6262 with
any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._